This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB05817/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05817/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05817/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05817
rdf:type
n3:Drug
n3:description
VNP40101M is a novel alkylating agent that is being evaluated for the treatment of acute myelogenous leukemia (AML. It is undergoing phase III development for the treatment of acute myeloid leukemia (AML) and earlier clinical trials for a range of other cancers.
n3:generalReferences
# Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S: Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol. 2007 Jan 1;25(1):25-31. Epub 2006 Dec 4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17146105
n3:group
investigational
n3:indication
Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), colorectal cancer, leukemia (lymphoid), leukemia (myeloid), lung cancer, myelodysplastic syndrome, pediatric indications, and solid tumors.
owl:sameAs
n10:DB05817
dcterms:title
VNP 40101M
adms:identifier
n7:3081349 n8:2338969 n11:DB05817
n3:mechanismOfAction
VNP40101M is a small molecule that works by damaging DNA. It releases the DNA chloroethylating agent 90CE after entering the blood stream. 90CE chloroethylates the O6 position of guanine residues, ultimately resulting in an interstrand DNA cross-link. Interstrand DNA cross-links are difficult to repair and are toxic to cells. VNP40101M demonstrates a broad spectrum of anticancer activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan. In preclinical studies, Cloretazine (VNP40101M) has been combined with other anticancer agents such as cytarabine (Ara-C). In addition, Cloretazine (VNP40101M) or its metabolite, has been shown to be capable of crossing the blood brain barrier in preclinical models.
n3:IUPAC-Name
n4:271B4746-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B474C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B474B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4748-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4749-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B474A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4744-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4742-363D-11E5-9242-09173F13E4C5 n4:271B4745-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4743-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4752-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4753-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B474D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B474E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4750-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B474F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4751-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4757-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4759-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B475A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4756-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4755-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4758-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4747-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4754-363D-11E5-9242-09173F13E4C5